The global diabetes drugs market was valued at USD 88.32 billion in 2024 and is expected to expand significantly. Projections indicate that the market will grow from USD 101.48 billion in 2025 to USD 233.84 billion by 2032, demonstrating a compound annual growth rate (CAGR) of 12.7% during the forecast period.
Request a Free Sample PDF Brochure of Diabetes Drugs Market: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100570
In its latest study, Fortune Business Insights offers an in-depth analysis of the global Diabetes Drugs Market for the forecast period of 2025–2032. The report highlights key drivers, challenges, opportunities, and market trends. Additionally, the report provides market share insights expressed in both value and volume for the various segments.
In July 2024, Novo Nordisk A/S received the Complete Response Letter (CRL) for the Biologics License Application (BLA) concerning once-weekly basal insulin icodec for diabetes treatment in the U.S. This regulatory decision highlights the increasing demand for innovative diabetes treatments and stringent regulatory approvals in the pharmaceutical industry.
The global diabetes drugs market is driven by several factors, including: